Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
Date:7/29/2009

g the addition of new products, including potassium-chloride extended-release capsules. Generic other revenue decreased $25.0 million to $7.4 million. Generic other revenue for the second quarter 2008 included a $15.0 million sales milestone from Barr Pharmaceuticals, Inc. following a 1999 legal settlement.

Adjusted Generic gross profit was $175.2 million in the second quarter of 2009, compared to $138.5 million in the second quarter of 2008 and $170.5 million in the first quarter of 2009. Adjusted Generic gross profit for the second quarter excludes approximately $8.1 million in costs related to Watson's Global Supply Chain Initiative and was positively influenced by the launch of new products and product mix.

Generic research and development expense increased $0.8 million or three percent to $29.9 million. Watson currently has approximately 60 ANDAs on file with the Food and Drug Administration (FDA).

    Brand Segment Information

                                  Three Months Ended      Six Months Ended
                                       June 30,               June 30,
                                       --------               --------
     (Unaudited; $in millions)      2009      2008        2009        2008
                                    ----      ----        ----        ----
     Brand Segment Contribution
     Product sales                 $97.6    $101.5      $195.8      $200.5
     Other revenue                  17.7      16.5        31.5        32.8
                                    ----      ----        ----        ----
       Net revenue                 115.3     118.0       227.3       233.3
     Operating expenses:
       Cost of sales                22.0      24.4        46.2        51.9
       Research and development     12.7      10.1        24.9        25.5
       Selling and marketing        39.1      29.6        76.0        57.6
          
'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
2. Watson CFO Mark W. Durand to Take Leave of Absence
3. Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
4. Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
5. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
6. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
7. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
8. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
9. Watson to Acquire Arrow Group
10. Watson Files FDA Application for Generic Mucinex(R) D
11. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Paul, MN (PRWEB) September 02, 2014 ... been refined and specially formulated, while preserving the foundation ... solutions for hair loss and scalp problems. There is ... on the market today. , Hair loss is a ... ages. Until now, options for treatment have been limited ...
(Date:9/2/2014)... YOUNGSTOWN, Ohio (PRWEB) September 02, 2014 Humility ... at Home, Sept. 18 at St. Elizabeth Health Center, 1044 ... that provides information about more than 200 common health problems ... family, preventing illness and injury, and advice on when to ... 11 a.m. to noon in the Youngstown Room; the evening ...
(Date:9/2/2014)... announce that the following papers will be published ... 2014, taking place in Barcelona, Spain, 30 August ... biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting ... single-blind, non-inferiority trial, Windecker et al , ... polymer, and drug release have improved clinical outcomes ...
(Date:9/2/2014)... Researchers in New Delhi, India have published a paper on ... asbestos-contaminated work clothes for just 3 months as a child. ... a new article. Click here to read it now. ... patient was diagnosed with mesothelioma after complaining of ... come in contact with her miner father’s dirty work clothes ...
(Date:9/2/2014)... Headaches, both chronic and acute ruin lives. They can ... friends, sleeping and just coping well with daily activities. ... worldwide. The medications prescribed for these conditions frequently don’t ... cases of headache and back pain are of a mechanical ... detect and fix the cause. , When a sports ...
Breaking Medicine News(10 mins):Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Physical Therapists in Houston Learn Pain Relief Techniques 2
... 13 Ruth W. Messinger, president of American ... today calling on the international community to actively ... into Darfur so workers can continue providing critical ... displaced persons throughout Darfur and Chad."The already fragile ...
... earning the doctor of optometry degree are encouraged to attend the ... and the N.C. State Education Assistance Authority. Conferences are scheduled ... East ... 10:00 a.m. - 12:00 noon, Tuesday, March 24, 2009 in the ...
... 20th Annual AIDS Walk Houston for Living Positive By DesignHOUSTON, ... series "Project Runway," is visiting Houston for the 20th Annual ... his national HIV and AIDS education initiative. On Sunday, ... helps to support more than 100,000 people with HIV and ...
... million gift for its campaign to build a children,s, ... Mission Bay campus, near downtown San Francisco. This is ... hospital fundraising campaign and among the largest gifts in ... percent match to encourage support from other philanthropists, was ...
... Clinical Care Options (CCO), a leader in education ... information provider, have been named the official providers of ... AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention ... 2009, and the XVIII International AIDS Conference in Vienna, ...
... shift to web news -LITTLE FALLS, N.J., March 13 ... reports on the closing and downsizing of many U.S. ... its list of 10 major daily papers most likely to fold ... New York Times reports that three papers ...
Cached Medicine News:Health News:Optometry Career Conferences Set for Five N.C. Campuses in March 2Health News:'Project Runway' Designer in Houston to Educate About Living With HIV and Combat Stigma Associated With the Disease 2Health News:'Project Runway' Designer in Houston to Educate About Living With HIV and Combat Stigma Associated With the Disease 3Health News:UCSF Medical Center receives $125 million gift to build new hospital 2Health News:UCSF Medical Center receives $125 million gift to build new hospital 3Health News:UCSF Medical Center receives $125 million gift to build new hospital 4Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 2Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 3Health News:Print Media Under Siege - Are Readers Disappearing? 2
(Date:9/2/2014)... 2014  Boston Scientific Corporation (NYSE: ... to purchase the Interventional business of Bayer AG. ... to offer physicians and healthcare systems a more ... conditions. The addition of the Bayer ... the Boston Scientific strategy to provide a comprehensive ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on its ... device market, Frost & Sullivan recognizes Novian Health, ... Sullivan Award for Technology Innovation Leadership. Novian Health ... and malignant tumors with its proprietary technology, Novilase ... a reliable, accurate, and easy-to-control ultrasound-guided thermo ablation ...
(Date:9/2/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the Morgan Stanley Global ... a.m. ET. The conference will be held at the ... City . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... ABBOTT PARK, Ill., April 21 Abbott (NYSE: ... strengthening its pharmaceutical pipeline in immunology and oncology. , ... The acquisition provides Abbott with ... that complement its existing diverse oncology program.  The new Abbott compounds ...
... Magellan Biosciences, Inc., an emerging leader in clinical ... first to offer minocycline and telavancin on IVD-labeled microbroth ... (FDA) has cleared TREK-brand Sensititre MIC plates for testing ... as well as telavancin against Gram positive bacterial isolates ...
Cached Medicine Technology:Abbott Completes Acquisition of Facet Biotech 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: